BlueCrest Capital Management’s Novavax NVAX Stock Holding History

BlueCrest Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,403	Closed	-$498K	–	346
2021 Q3	$498K	Buy	2,403 +476	+25%	+$105K	0.01%	289
2021 Q2	$409K	Buy	+1,927	New	+$353K	0.01%	443
2018 Q4	–	Sell	-2,880	Closed	-$108K	–	1243
2018 Q3	$108K	Buy	+2,880	New	+$81.1K	﹤0.01%	1380
2018 Q1	–	Sell	-548	Closed	-$14K	–	1593
2017 Q4	$14K	Sell	548 -3,857	-88%	-$94.1K	﹤0.01%	796
2017 Q3	$100K	Sell	4,405 -7,557	-63%	-$169K	﹤0.01%	789
2017 Q2	$275K	Buy	+11,962	New	+$235K	0.01%	711
2016 Q2	–	Sell	-1,275	Closed	-$132K	–	991
2016 Q1	$132K	Buy	+1,275	New	+$137K	0.01%	702

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlueCrest Capital Management's NVAX Position: Q4 2021 in Review

BlueCrest Capital Management sold out of Novavax (NVAX) in Q4 2021, closing a stake of 2,403 shares — an estimated $498K sold.

BlueCrest Capital Management first reported a position in NVAX in Q1 2016 and held it in 7 quarters. The position peaked at $498K in Q3 2021. 429 funds tracked by Wall St. Rank hold NVAX as of Q4 2021.

BlueCrest Capital Management reported no remaining Novavax position as of Q4 2021 after selling out during the quarter.
BlueCrest Capital Management sold 2,403 Novavax shares in Q4 2021, an estimated $498K.
BlueCrest Capital Management first reported a position in Novavax in Q1 2016 and held it in 7 quarters.
BlueCrest Capital Management's Novavax position peaked at $498K in Q3 2021.
429 funds tracked by Wall St. Rank held Novavax as of Q4 2021.

Based on BlueCrest Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.